



SHUKRA

PHARMACEUTICALS LTD.

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

31st July 2025

Scrip Code: 524632

Dear Sir/Madam,

Sub: Intimation of Board Meeting pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on **August 13, 2025** at the Registered Office of the Company to consider and approve the following: -

1. Unaudited financial result for the quarter ended on June 30, 2025 along with the Limited Review Report of the Auditor pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.
2. Any other business with the permission of Chairman.

In terms of the Company's Code of Conduct for Prevention of Insider Trading, the "Trading Window" for dealing in securities of the Company has been closed from July 01, 2025 till the end of 48 hours after the declaration of the Financial Results of the Company for the quarter ended on June 30, 2025.

You are requested to take the above information on records and disseminate the same.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited

bp Patel
Bhoomiben Patel
Director
DIN: 08316893



CIN : L24231GJ1993PLC019079

Email : info@shukrapharmaceuticals.com

Website : www.shukrapharmaceuticals.com

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad-380 054.

Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317